Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.
Abraham JE, Guo Q, Dorling L, Tyrer J, Ingle S, Hardy R, Vallier AL, Hiller L, Burns R, Jones L, Bowden SJ, Dunn JA, Poole CJ, Caldas C, Pharoah PP, Earl HM. Abraham JE, et al. Among authors: vallier al. Clin Cancer Res. 2014 May 1;20(9):2466-75. doi: 10.1158/1078-0432.CCR-13-3232. Epub 2014 Mar 5. Clin Cancer Res. 2014. PMID: 24599932
Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients.
Gounaris I, Provenzano E, Vallier AL, Hiller L, Iddawela M, Hilborne S, Taylor K, Britton P, Earl HM, Sinnatamby R. Gounaris I, et al. Among authors: vallier al. Breast Cancer Res Treat. 2011 Jun;127(2):459-69. doi: 10.1007/s10549-011-1454-x. Epub 2011 Mar 25. Breast Cancer Res Treat. 2011. PMID: 21437610
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.
Earl HM, Vallier AL, Hiller L, Fenwick N, Young J, Iddawela M, Abraham J, Hughes-Davies L, Gounaris I, McAdam K, Houston S, Hickish T, Skene A, Chan S, Dean S, Ritchie D, Laing R, Harries M, Gallagher C, Wishart G, Dunn J, Provenzano E, Caldas C; Neo-tAnGo Investigators. Earl HM, et al. Among authors: vallier al. Lancet Oncol. 2014 Feb;15(2):201-12. doi: 10.1016/S1470-2045(13)70554-0. Epub 2013 Dec 19. Lancet Oncol. 2014. PMID: 24360787 Free article. Clinical Trial.
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.
Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, Abraham J, Thomas J, Provenzano E, Hughes-Davies L, Gounaris I, McAdam K, Chan S, Ahmad R, Hickish T, Houston S, Rea D, Bartlett J, Caldas C, Cameron DA, Hayward L; ARTemis Investigators. Earl HM, et al. Among authors: vallier al. Lancet Oncol. 2015 Jun;16(6):656-66. doi: 10.1016/S1470-2045(15)70137-3. Epub 2015 May 11. Lancet Oncol. 2015. PMID: 25975632 Free article. Clinical Trial.
A Bayesian adaptive design for biomarker trials with linked treatments.
Wason JM, Abraham JE, Baird RD, Gournaris I, Vallier AL, Brenton JD, Earl HM, Mander AP. Wason JM, et al. Among authors: vallier al. Br J Cancer. 2015 Sep 1;113(5):699-705. doi: 10.1038/bjc.2015.278. Epub 2015 Aug 11. Br J Cancer. 2015. PMID: 26263479 Free PMC article.
A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities.
Abraham JE, Hiller L, Dorling L, Vallier AL, Dunn J, Bowden S, Ingle S, Jones L, Hardy R, Twelves C, Poole CJ, Pharoah PD, Caldas C, Earl HM. Abraham JE, et al. Among authors: vallier al. BMC Med. 2015 Dec 29;13:306. doi: 10.1186/s12916-015-0547-5. BMC Med. 2015. PMID: 26715442 Free PMC article.
Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.
Ali HR, Dariush A, Provenzano E, Bardwell H, Abraham JE, Iddawela M, Vallier AL, Hiller L, Dunn JA, Bowden SJ, Hickish T, McAdam K, Houston S, Irwin MJ, Pharoah PD, Brenton JD, Walton NA, Earl HM, Caldas C. Ali HR, et al. Among authors: vallier al. Breast Cancer Res. 2016 Feb 16;18(1):21. doi: 10.1186/s13058-016-0682-8. Breast Cancer Res. 2016. PMID: 26882907 Free PMC article. Clinical Trial.
The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study.
Dorling L, Kar S, Michailidou K, Hiller L, Vallier AL, Ingle S, Hardy R, Bowden SJ, Dunn JA, Twelves C, Poole CJ, Caldas C, Earl HM, Pharoah PD, Abraham JE. Dorling L, et al. Among authors: vallier al. PLoS One. 2016 Jul 8;11(7):e0158984. doi: 10.1371/journal.pone.0158984. eCollection 2016. PLoS One. 2016. PMID: 27392074 Free PMC article. Clinical Trial.
Trastuzumab-associated cardiac events in the Persephone trial.
Earl HM, Vallier AL, Dunn J, Loi S, Ogburn E, McAdam K, Hughes-Davies L, Harnett A, Abraham J, Wardley A, Cameron DA, Miles D, Gounaris I, Plummer C, Hiller L. Earl HM, et al. Among authors: vallier al. Br J Cancer. 2016 Dec 6;115(12):1462-1470. doi: 10.1038/bjc.2016.357. Epub 2016 Nov 22. Br J Cancer. 2016. PMID: 27875516 Free PMC article. Clinical Trial.
25 results